Identification
- Summary
Acrivastine is an antihistamine agent used for the symptomatic relief of seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.
- Brand Names
- Semprex-D
- Generic Name
- Acrivastine
- DrugBank Accession Number
- DB09488
- Background
Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia.
Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Acrivastine (DB09488)
- Weight
- Average: 348.4382
Monoisotopic: 348.183778022 - Chemical Formula
- C22H24N2O2
- Synonyms
- (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic acid
- acrivastina
- Acrivastine
- External IDs
- BW 825C
- BW A825C
- BW-825C
- BW-A825C
- BW825C
- BWA825C
Pharmacology
- Indication
For the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Seasonal allergic rhinitis Combination Product in combination with: Pseudoephedrine (DB00852) •••••••••••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AHistamine H1 receptor antagonistHumans - Absorption
Acrivastine was absorbed rapidly from the combination capsule following oral administration and was as bioavailable as a solution of acrivastine. After administration of SEMPREX-D Capsules, maximum plasma acrivastine concentrations were achieved at 1.14 ± 0.23 hour.
- Volume of distribution
0.46 ± 0.05 L/kg
- Protein binding
Acrivastine binding to human plasma proteins was 50 ± 2.0%.
- Metabolism
- Not Available
- Route of elimination
A mass balance study in 7 healthy volunteers showed that acrivastine is primarily eliminated by the kidneys. Over a 72-hour collection period, about 84% of the administered total radioactivity was recovered in urine and about 13% in feces, for a combined recovery of about 97%.
- Half-life
The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.
- Clearance
2.9 ± 0.7 mL/min/kg
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Acrivastine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Acrivastine which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Images
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DUACT 8 MG/60 MG KAPSÜL, 30 ADET Acrivastine (8 mg) + Pseudoephedrine hydrochloride (60 mg) Capsule Oral GLAXOSMİTHKLİNE İLAÇLARI SAN. VE TİC. A.Ş. 1995-09-15 Not applicable Turkey 
Semprex D Acrivastine (8 mg/1) + Pseudoephedrine hydrochloride (60 mg/1) Capsule Oral Endo Pharmaceuticals Inc. 2012-01-26 2020-12-31 US 
Semprex-D Acrivastine (8 mg/1) + Pseudoephedrine hydrochloride (60 mg/1) Capsule Oral Ucb Inc 2008-05-27 Not applicable US 
Categories
- ATC Codes
- R06AX18 — Acrivastine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Styrenes
- Direct Parent
- Styrenes
- Alternative Parents
- Toluenes / Pyridines and derivatives / N-alkylpyrrolidines / Heteroaromatic compounds / Trialkylamines / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds show 3 more
- Substituents
- Amine / Amino acid / Amino acid or derivatives / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative show 15 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- pyridines, alpha,beta-unsaturated monocarboxylic acid, olefinic compound, N-alkylpyrrolidine (CHEBI:83168)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A20F9XAI7W
- CAS number
- 87848-99-5
- InChI Key
- PWACSDKDOHSSQD-IUTFFREVSA-N
- InChI
- InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
- IUPAC Name
- (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
- SMILES
- [H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0240231
- KEGG Drug
- D02760
- PubChem Compound
- 5284514
- PubChem Substance
- 310265225
- ChemSpider
- 4447574
- 19959
- ChEBI
- 83168
- ChEMBL
- CHEMBL1224
- ZINC
- ZINC000003776633
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Acrivastine
- FDA label
- Download (2.43 MB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Syrup Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00994 mg/mL ALOGPS logP 4.29 ALOGPS logP 1.71 Chemaxon logS -4.5 ALOGPS pKa (Strongest Acidic) 3.68 Chemaxon pKa (Strongest Basic) 8.63 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 53.43 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 115.08 m3·mol-1 Chemaxon Polarizability 39.09 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0059-1094000000-36c7ee976a5fd1123837 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0zfr-0339000000-28fa434ebc5636e07f04 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03e9-0091000000-ad2ea82482f4162310c1 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0291000000-64ea054a51148452d3f9 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0090000000-5e7320211a1a258f4150 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0090000000-f3fbf635b967e5f422d8 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 212.6154257 predictedDarkChem Lite v0.1.0 [M-H]- 208.1881257 predictedDarkChem Lite v0.1.0 [M-H]- 195.27118 predictedDeepCCS 1.0 (2019) [M+H]+ 213.5808257 predictedDarkChem Lite v0.1.0 [M+H]+ 208.7824257 predictedDarkChem Lite v0.1.0 [M+H]+ 197.66675 predictedDeepCCS 1.0 (2019) [M+Na]+ 212.7241257 predictedDarkChem Lite v0.1.0 [M+Na]+ 208.8493257 predictedDarkChem Lite v0.1.0 [M+Na]+ 204.28596 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
Drug created at November 30, 2015 19:10 / Updated at February 21, 2021 18:52